According to a recent LinkedIn post from Lyfegen, the company is drawing attention to growing risks for patient access and launch strategies stemming from Most Favored Nation (MFN) drug pricing dynamics. The post cites examples including Amgen’s withdrawal of Repatha from Denmark and Insmed Inc.’s decision to pause EU and Japan launches of Brinsupri due to MFN-related uncertainty.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post also references reporting from Germany’s pharma association VFA that some manufacturers are postponing launches while they wait for clarity on U.S. pricing policy. It suggests that low prices in one reference market may become benchmarks for the United States, prompting firms to reassess global pricing and market-entry sequencing.
Lyfegen’s post positions this environment as a strategic challenge for manufacturers that must balance near-term revenue opportunities with longer-term pricing risk in major markets. For investors, the issues highlighted could translate into delayed product launches, altered market access plans, and potentially more volatile revenue timelines for affected biopharma companies.
The post further indicates that Lyfegen is offering its 2025 Drug Contracting Trends Report as a resource on how to navigate MFN-driven changes. This emphasis on contracting and pricing analytics may point to sustained demand for technology-enabled market access solutions, potentially reinforcing Lyfegen’s relevance as policy-driven pricing pressures intensify across global pharma markets.